Look for Drugs and Conditions

Representative Image

New Review Reveals that Antidepressants Reduce Anxiety, But Long-Term Impact Remains Unclear

A recent Cochrane analysis reveals that antidepressants significantly alleviate symptoms of generalised anxiety disorder (GAD) in controlled trial settings. However, the study identifies a major gap: insufficient data on the long-term effects of these drugs.

Millions of people throughout the world suffer from GAD, a condition characterised by excessive and persistent concern about daily living. National health agencies, notably the UK's National Institute for Health and Care Excellence (NICE), strongly suggest antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Despite their extensive use, individuals and healthcare professionals continue to have misconceptions about their purpose outside of treating depression. Furthermore, the stigma associated with the phrase 'antidepressants' discourages some people from obtaining proper treatment.

This Cochrane review included data from 37 randomised controlled trials with approximately 12,000 participants, the majority of which were done in high-income countries such as the United States and several European nations. The study discovered that antidepressants were much more effective than placebo in lowering anxiety symptoms, with a 41% greater response rate among those on medication. Notably, the antidepressant and placebo groups had identical dropout rates, indicating that the drugs were usually well tolerated.

"The research shows that antidepressants are highly effective in treating GAD, at least in the specific circumstances seen in trials," said Dr. Giuseppe Guaiana, Associate Professor of Psychiatry at Western University's Schulich School of Medicine & Dentistry and Chief of Psychiatry at St. Thomas Elgin General Hospital. "For people with generalised anxiety disorder and no other conditions, we have good evidence that antidepressants lead to clinically meaningful improvements over a one- to three-month period compared to placebo."

While the assessment found substantial evidence of short-term benefit, it also highlighted a paucity of long-term research. The majority of the trials included in the study lasted between 4 and 12 weeks, raising serious questions about the long-term efficacy and hazards of antidepressant usage.

"We don't have enough information on the potential long-term benefits and harms of antidepressants, even though people often take them for years," stated first author Katarina Kopcalic, who conducted the review at Western University. "This is an area that needs further exploration in future trials."

This evidence gap is especially troubling given that many patients with GAD also have other mental health disorders. In real-world clinical settings, GAD rarely exists in isolation, so it is critical to investigate how antidepressants work over long periods of time and in individuals with various disorders.

"We don't have enough evidence to say how effective they may be in patients with GAD alongside other mental health conditions, which is much more common in clinical practice," says Dr. Guaiana. "Most of the patients I see with GAD also have other mental health conditions, so future trials should investigate the effects of different treatment strategies on patients with multiple conditions."

The review emphasises the need for more study on the long-term effects of antidepressants in treating GAD, particularly in patients with coexisting mental health issues. Future research should include longer follow-up periods and investigate alternate treatment techniques, such as combination therapy with psychotherapy or other drugs.

For healthcare providers, the findings highlight the necessity of making educated decisions when prescribing antidepressants for anxiety disorders. Patients should be made aware of both the benefits and risks of long-term use. At the same time, researchers and policymakers must endeavour to close existing knowledge gaps in order to provide better long-term treatment solutions for persons affected with GAD.


0 Comments
Be first to post your comments

Post your comment

Related Articles

Ad 5
×